Author’s response to reviews

Title: Angiostatin generating capacity and anti-tumour effects of D-penicillamine and plasminogen activators

Authors:

Renate RRJ de Groot-Besseling (renatedegroot@gmail.com)
Iris IL Lamers-Elemans (i.elemans@cdl.umcn.nl)
Cathy CN Maass (C.Maass@pathol.umcn.nl)
Robert RMW de Waal (R.deWaal@pathol.umcn.nl)
Theo JM Ruers (T.Ruers@chir.umcn.nl)
Johan R Westphal (J.Westphal@obgyn.umcn.nl)

Version: 3 Date: 9 April 2006

Author's response to reviews:

Dear Editor,

Thank you for your message of March 23 on our MS 1823898158912486: Angiostatin generating capacity and anti-tumour effects of D-penicillamine and plasminogen activator.

Response to the comments of dr. Griffioen:
- p 21: A clear conclusion was added at the end of the discussion: ‘Finally, we conclude that D-penicillamine is not suitable for this type of therapy’.
- p 15: line 4-5: the absence of statistical significance of the results is now overtly mentioned: ‘The observed inhibition of tumour growth, however, was not statistically significant (p=0.08)’.
- p 18: line 4: this negative result is now described as: the observed inhibition....... ‘was far from convincing’.

Minor comments:
- p 19-20: The discussion on the findings by Merchan et al. and Agarwal et al. was rewritten, omitting statements on masking of the presence of angiostatin by other angiostatic factors. p.19: ‘In experiments performed by Merchan et al., it was shown that anti-angiogenic activity induced in plasma by tPA and captopril treatment, could not be abolished by removal of angiostatin, suggesting the generation of other anti-angiogenic molecules as a result of the treatment.’ was deleted.

In figure 5 the exact number of mice per group has now been mentioned for the different treatment modalities.

Best regards,

Renate de Groot